United Therapeutics Corporation
1110 Spring Street
266 articles with United Therapeutics Corporation
United Therapeutics Corporation To Report Fourth Quarter And Annual 2018 Financial Results Before The Market Opens On Wednesday, February 27, 2019
United Therapeutics Corporation announced that it will report its fourth quarter and annual 2018 financial results before the market opens on Wednesday, February 27, 2019.
Survival Data From FREEDOM-EV Study of Orenitram Presented at the Pulmonary Vascular Research Institute Annual World Congress
United Therapeutics Corporation today announced that key data from the FREEDOM-EV study of Orenitram® extended-release tablets were shared during an oral presentation at the Pulmonary Vascular Research Institute Annual World Congress on Pulmonary Vascular Disease in Barcelona, Spain.
United Therapeutics Corporation announced the closing of the transactions contemplated by its license agreement with Arena Pharmaceuticals, Inc. (Nasdaq: ARNA).
Arena Pharmaceuticals Announces Closing of Global License Agreement with United Therapeutics for Ralinepag
Arena Pharmaceuticals, Inc. announced the closing of the global license agreement with United Therapeutics Corporation for the Arena-discovered, Phase 3 investigational drug candidate ralinepag, a next-generation, oral, selective and potent prostacyclin receptor agonist for the treatment of pulmonary arterial hypertension
United Therapeutics Corporation announced today that Martine Rothblatt, Ph.D., Chairman and Chief Executive Officer of United Therapeutics, will provide an overview and update on the company's business at the 37th Annual J.P. Morgan Healthcare Conference in San Francisco, California.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of United Therapeutics Corporation - UTHR
Pomerantz LLP is investigating claims on behalf of investors of United Therapeutics Corporation ("United Therapeutics" or the "Company") (NASDAQ: UTHR).
United Therapeutics Corporation (NASDAQ: UTHR) announced today that Health Canada has approved PrUnituxin (dinutuximab for injection), in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin-2 (IL-2), and 13-cis-retinoic acid (RA)
Arena will receive $800M upfront, and is eligible to receive low double-digit tiered royalties, plus up to $400M in milestone payments
11/15/2018United Therapeutics bets a significant amount of money on the potential commercialization of ralinepag.
CollPlant Announces Closing of Global Licensing and Commercialization Agreement With United Therapeutics for 3D Bioprinting of Solid-Organ Scaffolds for Human Transplants
Collaboration Combines CollPlant’s Proprietary rhCollagen-based BioInk Technology and United Therapeutics’ Regenerative Medicine and Organ Manufacturing Capabilities
United Therapeutics Corporation announced today the appointment of Nilda Mesa to its Board of Directors as an independent director.
United Therapeutics Corporation today announced its financial results for the quarter ended September 30, 2018.
United Therapeutics Corporation To Report Third Quarter 2018 Financial Results Before The Market Opens On Wednesday, October 31, 2018
United Therapeutics Corporation announced today that it will report its third quarter 2018 financial results before the market opens on Wednesday, October 31, 2018.
CollPlant and United Therapeutics Announce Global Licensing and Commercialization Agreement for 3D Bioprinting of Solid-Organ Scaffolds for Human Transplant
Collaboration Combines CollPlant's Proprietary rhCollagen-based Bioink Technology and United Therapeutics' Regenerative Medicine and Organ Manufacturing Capabilities
United Therapeutics Corporation and MannKind Corporation today announced the closing of their pending worldwide exclusive license and collaboration agreement for the development and commercialization of Treprostinil Technosphere®, a dry powder formulation of treprostinil being developed for the treatment of pulmonary arterial hypertension.
United Therapeutics Corporation announced today that it will host Science Day 2018 in New York City on Monday, September 24th, beginning at approximately 10:00 A.M. Eastern Time and ending at approximately 4:00 P.M. Eastern Time.
Samumed And United Therapeutics Announce North American License Agreement For Samumed's IPF Drug Candidate
Samumed LLC has entered an exclusive license agreement with United Therapeutics Corporation (Nasdaq: UTHR) for North American rights to Samumed's SM04646, being developed for the treatment of idiopathic pulmonary fibrosis (IPF).
Exclusive license agreement for Treprostinil Technosphere®; $95 million in upfront and milestone payments
Correvio Pharma Corp. today highlighted that United Therapeutics (NASDAQ: UTHR) has completed its acquisition of SteadyMed Ltd., Correvio's partner and the licensor of Trevyent®.
MannKind Corporation, based in Westlake Village, California, and United Therapeutics, located in Silver Spring, Maryland, signed a worldwide exclusive license and collaboration deal to develop and commercialize a dry powder formulation of treprostinil.